Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months

Basit Öğe Kaydı
dc.contributor.authorSaydam, Gueray
dc.contributor.authorHaznedaroglu, Ibrahim C.
dc.contributor.authorTemiz, Yesim
dc.contributor.authorSoysal, Teoman
dc.contributor.authorSucak, Gulsan
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorOzdogu, Hakan
dc.date.accessioned2024-04-24T17:49:57Z
dc.date.available2024-04-24T17:49:57Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description.abstractThis retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72 +/- 171.29, 714.29 +/- 106.90, and 569.23 +/- 160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.en_US
dc.identifier.endpage204en_US
dc.identifier.issn1306-133X
dc.identifier.issue4en_US
dc.identifier.startpage195en_US
dc.identifier.urihttps://hdl.handle.net/11468/23119
dc.identifier.volume19en_US
dc.identifier.wosWOS:000273130700001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDasatiniben_US
dc.subjectCompassionate Use Programen_US
dc.subjectPhiladelphia Positive Leukemiasen_US
dc.subjectCmlen_US
dc.titleRetrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Monthsen_US
dc.titleRetrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu